C12Y 204/02031
Nad+-protein-arginine adp-ribosyltransferase
Official title: NAD+-protein-arginine ADP-ribosyltransferase (2.4.2.31)
C12Y204/02031 (Nad+-protein-arginine adp-ribosyltransferase) appears on 4 US grants and 7 published applications in this corpus.
Search patents in C12Y- Granted patents
- 4
- Published applications
- 7
- Assignees
- 3
- Inventors
- 7
- Latest grant
- 21 Jan 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 2 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 2 |
| 2025 | 1 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Use of pertussis toxin as a therapeutic agent21 Jan 2025US 12,201,678 B2Dignity Health
- Use of pertussis toxin as a therapeutic agent5 Dec 2023US 11,833,191 B2Dignity Health
- Use of pertussis toxin as a therapeutic agent1 Dec 2020US 10,849,961 B2Dignity Health
- Use of pertussis toxin as a therapeutic agent24 Mar 2020US 10,596,233 B2Dignity Health
- Compositions and methods for treating and preventing headaches30 Jul 2026US 2026/0217773 A1Neurocarrus Inc.
- Furin-cleavable delivery constructs27 Mar 2025US 2025/0099599 A1Thornhill Therapeutics, Inc.
- Use of pertussis toxin as a therapeutic agent11 Jul 2024US 2024/0226244 A9Dignity Health
- Use of pertussis toxin as a therapeutic agent25 Apr 2024US 2024/0131119 A1Dignity Health
- Use of pertussis toxin as a therapeutic agent11 Mar 2021US 2021/0069302 A1Dignity Health
Most cited
By later US patents